Combining CAF, L-FABP and NGAL as a Potentially Diagnostic Model for Acute Kidney Injury.
NCT ID: NCT04555382
Last Updated: 2020-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2020-08-15
2022-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This observational cohort study included one hundred patients who had been in ICU from the Second Affiliated Hospital of Zhejiang University School of Medicine between August 2020 and August 2022. Blood and urine samples were collected every 12 hours until 7 days. The time of staying with ICU less than 2 days were removed. CAF, L-FABP and NGAL was measured based on the platform of Chemiluminescent Immunoassay, and assessed the diagnostic value of the occurrence of AKI. By constructing an effective diagnostic model to provide effective clinical decision-marking for early intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
NCT02121470
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
NCT02049125
RDRI and NGAL in Acute Kidney Injury in Abdominal Surgery
NCT05929573
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
NCT04008810
NGAL in Prediction of AKI and Patient Outcomes
NCT06691607
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Collecting the blood and urine samples of the patients regularly every twelve hours, centrifuging samples in 3000rpm for 5 minutes, freezing at -80℃, all patients' clinical information should be recorded by name, age ,sex, BMI index, hypertension, diabetes, cardiac disease, and so on. All patients have written informed contents and this study was approved by the Second Affiliated Hospital of Zhejiang University School of Medicine.NGAL, CAF and L-FABP was measured by chemiluminescent immunoassay with Robust i1000.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AKI group
this group are included patients who have not occured acute kidney injury at first, however acute kidney injury are occured soon afterwards during the observation period.
Blood and Urine
Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
non-AKI group
this group are included patients who have not occured acute kidney injury during the observation period.
Blood and Urine
Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood and Urine
Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. renal dialysis and plasma exchange were never occured when patients were included in the study;
3. patients who were included in the study stayed at two days in ICU.
Exclusion Criteria
2. the serum creatinine was increased above reference range before ICU admission;
3. kidney-related diseases were existed before ICU admission.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tao Zhihua
Role: STUDY_CHAIR
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-791
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.